IsoRay, Inc. (NYSEMKT:ISR) CEO Thomas C. Lavoy purchased 20,000 shares of the stock in a transaction dated Thursday, November 17th. The stock was acquired at an average price of $0.60 per share, for a total transaction of $12,000.00. Following the completion of the transaction, the chief executive officer now directly owns 163,523 shares of the company’s stock, valued at $98,113.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

IsoRay, Inc. (NYSEMKT:ISR) traded down 1.7217% during mid-day trading on Monday, hitting $0.5651. 75,363 shares of the stock traded hands. The stock has a 50 day moving average price of $0.63 and a 200 day moving average price of $0.77. IsoRay, Inc. has a 12-month low of $0.48 and a 12-month high of $1.30. The firm’s market cap is $31.09 million.

About IsoRay

IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.

Receive News & Stock Ratings for IsoRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay Inc. and related stocks with our FREE daily email newsletter.